HEATHER DEL VALLE: Open Payments
NPI 1699329201 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,848 in 94 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $3,090 · 2025 $2,848
Food & beverage: $2,747Education: $101
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 16 | $500 |
| Neurocrine BioSciences, Inc. | 18 | $498 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $353 |
| Janssen Pharmaceuticals, Inc | 3 | $317 |
| E.R. Squibb & Sons, L.L.C. | 13 | $301 |
| Otsuka America Pharmaceutical, Inc. | 7 | $262 |
| ABBVIE INC. | 7 | $226 |
| Vanda Pharmaceuticals Inc. | 7 | $181 |
| Alkermes, Inc. | 5 | $102 |
| Lundbeck LLC | 5 | $95 |
Products named: INGREZZA, CAPLYTA, REXULTI, INVEGA SUSTENNA, COBENFY, AUSTEDO XR, VRAYLAR, FANAPT.
Industry payments across CA — which companies pay providers there.
